4.Crecon Report 2013.In Japan's Pharmaceutical Wholesale Industry Association(JPWA)Website,Data,2014.
[5]
5.Dearment,A.,Pharmacists Are Face of Healthcare in Community. RX Impact,March 2012,p.3.
[6]
6.Dulleck,U.and Kerschbamer R.,On Doctors,Mechanics,and Computer Specialists: The Economics of Credence Goods.Journal of Economic Literature,Vol.44,No.1,2006,pp.5-42.
[7]
7.Fujii,M.and M.Reich,Rising Medical Costs and the Reform of Japan's Health Insurance System.Health Policy,Vol.9,1988,pp.9-23.
[8]
8.Health Strategies Consultancy(HSC),Follow the Pill: Understanding the U.S.Commercial Pharmaceutical Supply Chain.The Kaiser Family Foundation,2005.
[9]
9.Holmstrom,B.and P.Milgrom,The Firm as an Incentive System.American Economic Review,Vol.84,1994,pp.972-991.
[10]
10.Iizuka,T.,Experts' Agency Problems: Evidence from the Prescription Drug Market in Japan.Rand Journal of Economics, Vol.38,No.3,2007,pp.844-862.
[11]
11.IMS Health,Channel Distribution by U.S.Spending.IMS Health Website,February 23,2012.
[12]
12.Japan Ministry of Health Labour and Welfare(JMHLW),Annual Health,Labour and Welfare Report 2012-2013.Tokyo: Japan Ministry of Health Labour and Welfare White Papers & Reports,2013,pp.1-72.
[13]
13.Kanavos,P.,W.Schurer and S.Vogler,The Pharmaceutical Distribution Chain in the European Union: Structure and Impact on Pharmaceutical Prices.European Commission,2011,Chapter 3.
15.Lopes,S.,Ch.Marty and B.Berdai,PHIS Pharma Profile France 2011- Pharmaceutical Health Information System.European Commission,2011.
[16]
16.Milgrom,P.and J.Roberts,Complementarities and Systems: Understanding Japanese Economic Organization.Estudios Economicos,Vol.9,No.1,1994,pp.3-42.
[17]
17.NHS,A Simple Guide to Payment by Results.UK Department of Health Website,25 March 2013.
[18]
18.OBIG,Surveying,Assessing and Analyzing the Pharmaceutical Sector in 25 EU Member States-Country Profiles: Germany.Luxembourg: European Communities,2006,pp.182-244.
[19]
19.OECD,Pharmaceutical Pricing Policies in a Global Market.OECD Publishing,2008,pp.102-105.
[20]
20.Office of Fair Trading(OFT),The Pharmaceutical Price Regulation Scheme: An OFT Market Study.London: Crown Copyright,2007.
[21]
21.Paris,V.and E.Docteur,Pharmaceutical Pricing and Reimbursement Policies in Germany.OECD Health Working Paper,No.39,2008.
[22]
22.Reich,M.,Why the Japanese Doesn't Export More Pharmaceuticals: Health Policy as Industry Policy.California Management Review,Vol.32,No.2,1990,pp.124-150.
[23]
23.Taylor,D.,M.Mrazek,and E.Mossialos,Regulating Pharmaceutical Distribution and Retail Pharmacy in Europe.In Mossialos,E.,M.Mrazek,and T.Walley(eds.),Regulating Pharmaceuticals in Europe: Striving for Efficiency,Equity and Quality.Berkshire: Open University Press,2004.
[24]
24.Topkis,D.,Minimizing a Submodular Function on a Lattice.Operations Research,Vol.26,1978,pp.305-321.
[25]
25.Topkis,D.,Equilibrium Points in Nonzero-sum n-Person Submodular Games.Siam Journal of Control and Optimization,Vol.17,No.6,1979,pp.773-787.
[26]
26.Van Ganse,E.,G.Chamba,G.Bruet,V.Becquart,C.Stamm,S.Lopes and Ch.Marty,PPRI Pharma Profile France 2008. European Commission,2008.
